延迟发作的帕金森症在孤立的条纹性心脏病发作后很常见
Hedda Holm1,2, Espen Dietrichs1,2, Juho Joutsa3,4
1Department of Neurology, Oslo University Hospital, Oslo, Norway.
Frontiers in neurology
|December 8, 2025
概括
迟发性帕金森症在孤立的条纹性心脏病发作后很常见,在一年内影响三分之二的患者. 这凸显了对中风患者进行仔细监测和评估是否发展帕金森症症状的必要性.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 脑卒中医学 脑卒中医学
背景情况:
- 之前对布塔米纳损伤后帕金森症的研究受限于邻近的大脑区域的参与和短时间的随访.
- 在孤立的条纹性心脏病发作后,帕金森病的真实发病率和特征仍然不清楚.
- 在之前的研究中缺乏系统的神经成像,这限制了对中风后帕金森症的理解.
研究的目的:
- 为了确定隔离性条纹性心脏病发作后帕金森症的发生率和时间.
- 在这个患者群体中描述帕金森症的临床特征.
- 利用全面的神经成像和纵向评估进行准确的评估.
主要方法:
- 奥斯陆大学医院的前性队列研究.
- 包括急性缺血性中风和孤立的状心脏病发作患者,不包括严重的神经缺陷 (NIHSS >= 6).
- 临床评估 (NIHSS,MDS-UPDRS,MoCA) 和神经成像 (MRI,FP-CIT SPECT) 在3个月和1年.
主要成果:
- 27%的患者在3个月内发展出帕金森症,在1年内增加到67%.
- 渐进的运动症状增加 (MDS-UPDRS) 与主要的副作用症状;认知功能保持稳定 (MoCA).
- 心脏病发作的体积和位置影响了运动症状的发展;所有患者都显示多巴胺激素吸收减少 ([123I]FP-CIT).
结论:
- 这项研究是首次在隔离性条纹性心脏病发作后系统地调查延迟发作的帕金森症.
- 帕金森症在患有隔离性条纹性心脏病发作的患者中比以前认为的更频繁.
- 研究结果强调了重复评估对于发现和管理中风后帕金森症的重要性.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K


